Salutaris Medical Devices
Tucson
About Salutaris Medical Devices
SMD is a clinical-stage radiotherapeutic company that has developed the BetaCurve™. This 510k-cleared device can deliver the optimal dose of strontium-90 beta rays to treat challenging disease activity at the back of the eye. SMD's BetaCurve™ has the potential to treat millions of people who suffer from: Advanced Macular Degeneration (wet-AMD) Chronic Central Serous Chorioretinopathy (CCSR) Choroidal Hemangiomas Early Small Ocular Melanoma Choroidal Dysplastic Nevi Wet-AMD is the leading cause of blindness amongst seniors worldwide. The current treatment (when available) is frequent lifetime eye injections directly into the eyeball. This therapy is expensive, unpleasant, and fails to deliver adequate results for many patients. Currently, SMD is focused 100% on treating the wet-AMD subtype that does not respond well to current injection therapy: PCV (polypoidal choroidal vasculopathy). Recently, the FDA cleared SMD to conduct a pivotal study for PCV. By becoming the first FDA-approved treatment for the PCV indication, we believe that SMD's radiotherapy will have a clear pathway to enter the $15 billion injection market (anti-VEGF monotherapy).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $7.5M
- Last round: Series Unknown (Feb 2018)
- Website: salutarismd.com
- Phone: (520) 638-7518
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/salutaris-medical-devices-173404 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.